The Myeloma Crowd
Research Initiative (MCRI)

  • TARGETING HIGH-RISK MYELOMA

We are desperately in need of new options. And since we “Can’t Wait for a Cure,” we created a research initiative to find and fund the best, innovative research with high-risk patients in mind.

The Myeloma Crowd Research Initiative (MCRI) is a new approach to funding cancer research; combining the skill and knowledge of leading myeloma specialists with the patient perspective and supportive patient social communities to select and fund promising research projects in myeloma. Our goal is to find and fund a cure for multiple myeloma.

STAGES

TOP 10 PROPOSALS

Craig Hofmeister, MD
Craig Hofmeister, MDCAR T-Cell Therapy
Guenther Koehne, MD
Guenther Koehne, MDSafer Allo Plus Immunotherapies for High-Risk and PCL Patients
Robert Orlowski, MD, PhD
Robert Orlowski, MD, PhDNew Targeted Solution for del17p Myeloma Patients
Bruno Paiva, PhD
Bruno Paiva, PhDIdentifying Chemo Resistant Myeloma for the Development of Effective Treatment
Ivan Borrello, MD, PhD
Ivan Borrello, MD, PhDT-Cell Therapy with Autologous Transplant for Normal and High-Risk Patients
Guido Tricot, MD, PhD & Team
Guido Tricot, MD, PhD & TeamNew Solutions for 14;16 and 14;20 Patients with Targeted Treatment
Kelvin Lee, MD & Team
Kelvin Lee, MD & TeamCD28 Target and 14;16 Potential Cure with PIM2 Kinase Inhibitor
Gareth Morgan, MD, PhD
Gareth Morgan, MD, PhDYour Own Mouse Avatar - How to Find the Very Best Treatment for You Faster
Hermann Einsele, MD & Team
Hermann Einsele, MD & TeamCAR T-Cell Therapy Targeting CS1 and BCMA
Frits van Rhee, MD, PhD & Team
Frits van Rhee, MD, PhD & TeamThe Measles Virus in Multiple Myeloma

WINNERS

CAR T-CELL THERAPY  TARGETING CS1 AND BCMA

DR. HERMANN EINSELE & DR. MICHAEL HUDECEK University of Würzburg

Einsele-and-Hudecek-500x300

CAR T-Cells are a hot new area of research in blood cancers. This study takes a patient’s own white blood cells from a blood sample and engineers them to target specific receptors – CS1 and BMCA – common proteins found on the surface of myeloma cells. The T Cells are then given back to the patient after a two-week period. CAR T therapy is all at once a cell therapy, gene therapy and immunotherapy. This study will be applicable for high-risk patients who have failed standard myeloma therapies but will also be appropriate for normal risk patients regardless of genetic features.

T-CELL THERAPY WITH AUTOLOGOUS TRANSPLANT

DR. IVAN BORRELLO Johns Hopkins Sidney Kimmell Comprehensive Cancer Center

Dr.-Ivan-Borrello-500x300

Dr. Ivan Borrello is working to create a patient-specific immunotherapy using enhanced T cells from the patient’s own bone marrow, for truly personalized medicine. Using white blood cells from a bone marrow sample, he is able to expand the cells a hundred-fold in the presence of the tumor cells. After these T-Cells are expanded, they are given back to the patient on day 3 or 4 of autologous transplant. When they are reintroduced, they leverage the body’s natural process to further expand more immune fighter cells and they target hundreds of proteins that could be causing tumor growth for that patient, not just a single protein. This is an open clinical study today for patients with high-risk genetic features.

FUNDRAISING

Our goal now is to grant each of these two studies $250,000 over a two-year period for a grand total of $500,000.

$49,661 of $500,000 Raised

To date, we’ve raised $431,703. Please help us fully fund these promising research projects by donating today.

ADVISORY BOARDS

Scientific Advisory Board

C. Ola Landgren, MD, PhD
C. Ola Landgren, MD, PhDChief, Myeloma Service at Memorial Sloan Kettering Cancer Center
Irene Ghobrial, MD, PhD
Irene Ghobrial, MD, PhDDirector, Michele & Stephen Kirsch Laboratory at Dana Farber Cancer Institute
Guido Tricot, MD, PhD
Guido Tricot, MD, PhDDirector, Bone Marrow Transplant and Myeloma Program at Holden Comprehensive Cancer Center, U of Iowa
Noopur Raje, MD, PhD
Noopur Raje, MD, PhDDirector, Multiple Myeloma Program at Raje Laboratory, Massachusetts General Hospital
Rafael Fonseca, MD
Rafael Fonseca, MDDirector, Fonseca Laboratory and Getz Family Professor of Cancer at Mayo Clinic Scottsdale
Robert Orlowski, MD, PhD
Robert Orlowski, MD, PhDDirector of Myeloma at University of Texas MD Anderson Cancer Center

Patient Advisory Board

Jenny Ahlstrom
Jenny AhlstromMyeloma Survivor; Founder of CrowdCare Foundation, Myeloma Crowd, and Myeloma Crowd Radio
Jim Omel, MD
Jim Omel, MDMyeloma Survivor; Support Group Leader; Leading Patient Advocate multiplemyelomablog.com
Gary Peterson
Gary PetersonMyeloma Survivor; Patient Advocate and Myeloma Survival Statics: myelomasurvival.com
Jack Aiello
Jack AielloMyeloma Survivor; Experienced Patient Advocate
Cynthia Chmielewski
Cynthia ChmielewskiMyeloma Survivor; Experienced Patient Advocate: @MyelomaTeacher
Eric Hansen
Eric HansenMyeloma Survivor; Experienced Patient Advocate

Communications Advisory Board

Mike Thompson, MD, PhD
Mike Thompson, MD, PhDMedical Director, Early Phase Cancer Research Program at Aurora Health Care

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: